EUVIMEDEUVIMED entdecken
Crossref

EE394 COST-CONSEQUENCE ANALYSIS OF UPADACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ATOPIC DERMATITIS IN COLOMBIA

Jazmin Pinzon

Value in Health · 2026-06 · 29 (6) · S138

DOI: 10.1016/j.jval.2026.03.688 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Value in Health, 2026-06. Verfasst von Jazmin Pinzon.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Pinzon, J. (2026). EE394 COST-CONSEQUENCE ANALYSIS OF UPADACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ATOPIC DERMATITIS IN COLOMBIA. Value in Health, 29(6), S138. https://doi.org/10.1016/j.jval.2026.03.688

Vancouver

Pinzon J. EE394 COST-CONSEQUENCE ANALYSIS OF UPADACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ATOPIC DERMATITIS IN COLOMBIA. Value in Health. 2026;29(6):S138. doi:10.1016/j.jval.2026.03.688

BibTeX
@article{Pinzon2026,
  author = {Pinzon, Jazmin},
  title = {EE394 COST-CONSEQUENCE ANALYSIS OF UPADACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ATOPIC DERMATITIS IN COLOMBIA},
  journal = {Value in Health},
  year = {2026},
  volume = {29},
  number = {6},
  pages = {S138},
  doi = {10.1016/j.jval.2026.03.688}
}
Kostenlos starten →